Regulation of biogenerics: a survey of viewpoints.
OBJECTIVE
'Biogenerics' regulation has brought about a heated debate within the EU as the first biopharmaceuticals are going off patent. This study aims to examine the opportunities and challenges offered by biogenerics by surveying the viewpoints of experts in regulatory agencies and in companies developing novel biopharmaceuticals and biogenerics.


METHODS
Oral interviews were conducted in 2002 and 2003 with experts including representatives of the European Generic Medicines Association (EGA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Brussels, three innovator biotech companies, and five other experts in Finland. Additionally, four biogenerics companies and one innovator company abroad answered a structured, written questionnaire.


CONCLUSIONS
According to this study, biogenerics should be regulated on a case-by-case basis. The interviewees were not unanimous as to whether comparability can be addressed and which are the most challenging areas for proving comparability. Immunogenicity was considered to be a major problem for biogenerics. Therefore, a requirement for an intensified monitoring of the safety profile during post-marketing was thought to be justified in many cases.
Nieminen
Outi
O
Laboratory of Biochemistry and Microbiology, Helsinki University of Technology, Espoo, FIN-02015-HUT, Finland.
Nordström
Katrina
K
D001688:Biological Products / Q000191:economics*; D001702:Biopharmaceutics; D002986:Clinical Trials as Topic; D003625:Data Collection; D016527:Drug Costs; D004342:Drug Hypersensitivity / Q000453:epidemiology; D004345:Drug Industry / Q000191:economics; D016568:Drugs, Generic / Q000191:economics*; D005060:Europe; D006077:Government Agencies; D007880:Legislation, Drug / Q000191:economics*
D001688:Biological Products; D016568:Drugs, Generic